Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.

Autor: Flipo M; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France., Frita R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Bourotte M; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.; BioVersys SAS, Lille, France., Martínez-Martínez MS; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Boesche M; Cellzome GmbH . A GSK Company, 69117 Heidelberg, Germany., Boyle GW; GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire SG12 ODP, UK., Derimanov G; GSK, Clinical Pharmacology and Experimental Medicine, 1250 South Collegeville Road, Collegeville, PA 19426, USA., Drewes G; Cellzome GmbH . A GSK Company, 69117 Heidelberg, Germany., Gamallo P; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Ghidelli-Disse S; Cellzome GmbH . A GSK Company, 69117 Heidelberg, Germany., Gresham S; GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire SG12 ODP, UK., Jiménez E; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., de Mercado J; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Pérez-Herrán E; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Porras-De Francisco E; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Rullas J; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Casado P; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Leroux F; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France., Piveteau C; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France., Kiass M; National Reference Center for Tuberculosis and Mycobacteria, Sciensano, Brussels, Belgium., Mathys V; National Reference Center for Tuberculosis and Mycobacteria, Sciensano, Brussels, Belgium., Soetaert K; National Reference Center for Tuberculosis and Mycobacteria, Sciensano, Brussels, Belgium., Megalizzi V; Microbiology, Bioorganic and Macromolecular Chemistry, Facult. de Pharmacie, Universit. Libre de Bruxelles, Brussels, Belgium., Tanina A; Microbiology, Bioorganic and Macromolecular Chemistry, Facult. de Pharmacie, Universit. Libre de Bruxelles, Brussels, Belgium., Wintjens R; Microbiology, Bioorganic and Macromolecular Chemistry, Facult. de Pharmacie, Universit. Libre de Bruxelles, Brussels, Belgium., Antoine R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Brodin P; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France., Delorme V; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Moune M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Djaout K; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Slupek S; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Kemmer C; BioVersys AG, Basel, Switzerland., Gitzinger M; BioVersys AG, Basel, Switzerland., Ballell L; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Mendoza-Losana A; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Lociuro S; BioVersys AG, Basel, Switzerland., Deprez B; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France., Barros-Aguirre D; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Remuiñán MJ; GSK, Tres Cantos R&D, PTM, Tres Cantos, 28760 Madrid, Spain., Willand N; Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France., Baulard AR; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France.

Publikováno v: Science translational medicine [Sci Transl Med] 2022 May 04; Vol. 14 (643), pp. eaaz6280. Date of Electronic Publication: 2022 May 04.

Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence.

Autor: Dutta NK; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Klinkenberg LG; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Vazquez MJ; Medical Department, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Segura-Carro D; Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Colmenarejo G; Molecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.; Biostatistics and Bioinformatics Unit, IMDEA Food Institute, Madrid, Spain., Ramon F; Molecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Rodriguez-Miquel B; Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Mata-Cantero L; Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Porras-De Francisco E; Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Chuang YM; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Rubin H; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Lee JJ; Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, CA, USA., Eoh H; Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, CA, USA., Bader JS; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Perez-Herran E; Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Mendoza-Losana A; Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain., Karakousis PC; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Publikováno v: Science advances [Sci Adv] 2019 Mar 20; Vol. 5 (3), pp. eaav2104. Date of Electronic Publication: 2019 Mar 20 (Print Publication: 2019).